Sentinel lymph node biopsy does not change melanoma-specific survival among patients with Breslow thickness greater than four millimeters.

Research output: Contribution to journalArticlepeer-review

Abstract

Management of patients with cutaneous melanoma in the absence of lymph node metastases is still controversial. The experience at the National Cancer Institute in Naples was analyzed to evaluate 3-year disease-free survival and overall survival for all patients who underwent sentinel lymph node biopsy (SLB) with Breslow thickness greater than 4 mm. Data from 359 sentinel biopsies performed in the past 5 years were reviewed to determine the effect of the treatment on disease-free survival and overall survival after stratifying patients for node status, tumor ulceration, and Breslow thickness. Statistical analysis showed a better 3-year survival for sentinel node-negative patients than for sentinel node-positive cases (88.4% and 72.9%, respectively; P

Original languageEnglish
JournalAnnals of Surgical Oncology
Volume11
Issue number3 Suppl
Publication statusPublished - Mar 2004

ASJC Scopus subject areas

  • Oncology
  • Surgery

Fingerprint Dive into the research topics of 'Sentinel lymph node biopsy does not change melanoma-specific survival among patients with Breslow thickness greater than four millimeters.'. Together they form a unique fingerprint.

Cite this